New · CUSIP 68403P203 · who reports it, how much, and how much it matters to them
9 of the 720 hedge fund managers we track reported shares of Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) on Form 13F for 30 June 2026. Between them they reported USD 14m. The largest position belongs to Gem Investment Advisors, at USD 9.6m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Gem Investment Advisors1 fund on PPLI.com | USD 9.6m | 5.9% |
| 2 | Boothbay Fund Management2 funds on PPLI.com | USD 2.8m | 0.0% |
| 3 | Renaissance Technologies13 funds on PPLI.com | USD 884,000 | 0.0% |
| 4 | Marshall Wace LLP84 funds on PPLI.com | USD 490,000 | 0.0% |
| 5 | Citadel Advisors32 funds on PPLI.com | USD 200,000 | 0.0% |
| 6 | Prelude Capital Management9 funds on PPLI.com | USD 157,000 | 0.0% |
| 7 | Millennium Management6 funds on PPLI.com | USD 105,000 | 0.0% |
| 8 | Engineers Gate Manager1 fund on PPLI.com | USD 61,077 | 0.0% |
| 9 | Hudson Bay Capital Management8 funds on PPLI.com | USD 49,375 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Gem Investment Advisors | USD 9.6m | 5.9% |
| 2 | Boothbay Fund Management | USD 2.8m | 0.0% |
| 3 | Prelude Capital Management | USD 157,000 | 0.0% |
| 4 | Renaissance Technologies | USD 884,000 | 0.0% |
| 5 | Engineers Gate Manager | USD 61,077 | 0.0% |
| 6 | Marshall Wace LLP | USD 490,000 | 0.0% |
| 7 | Citadel Advisors | USD 200,000 | 0.0% |
| 8 | Millennium Management | USD 105,000 | 0.0% |
| 9 | Hudson Bay Capital Management | USD 49,375 | 0.0% |
Oramed Pharmaceuticals Inc. trades under the symbol ORMP on the Nasdaq. Its CUSIP, the code used on Form 13F, is 68403P203.
9 of the 720 hedge fund managers PPLI.com tracks reported Oramed Pharmaceuticals Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Gem Investment Advisors (USD 9.6m), Boothbay Fund Management (USD 2.8m), Renaissance Technologies (USD 884,000), Marshall Wace LLP (USD 490,000) and Citadel Advisors (USD 200,000).
9 managers in our coverage reported it, and between them they run 156 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Gem Investment Advisors, where the position was 5.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Oramed Pharmaceuticals Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.